Literature DB >> 10869881

The genes for major psychosis: aberrant sequence or regulation?

A Petronis1.   

Abstract

A number of recent clinical and molecular observations in major psychosis indicate that epigenetic factors may be operational in the origin of major mental illness. This article further develops the idea that epigenetic factors may play an etiopathogenic role in schizophrenia and bipolar affective disorder. The putative role of epigenetic factors is shown by the epigenetic interpretation of genetic association studies of the genes for serotonin 2A (HTR2A) and the dopamine D3 (DRD3) receptors in schizophrenia. The idea of epigenetic polymorphism of genetic alleles is introduced, and it is argued that epigenetic variation may explain a number of controversial and unclear findings in allelic and genotypic association studies of HTR2A and DRD3. In linkage analyses of multiplex families with bipolar affective disorder (BPAD), different loci on chromosome 18 indicated co-segregation of alleles of one parental sex with the disease phenotype, and this finding implies that the epigenetic mechanism of genomic imprinting may be involved. Evidence for genomic imprinting provides the background for epigenetic cloning of BPAD risk factors by searching for differentially modified genes on chromosome 18. Finally, epigenetic studies could be relevant to the better understanding of the molecular action of antipsychotic medications. In addition to this, if epimutations are detected in major psychosis, epigenetic treatment directed at correction of epigenetic status of a specific brain gene may eventually be developed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869881     DOI: 10.1016/S0893-133X(00)00127-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

Review 1.  Paternal factors and schizophrenia risk: de novo mutations and imprinting.

Authors:  D Malaspina
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

Review 2.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

3.  Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies.

Authors:  Haiyan Zhou; Martin Brockington; Heinz Jungbluth; David Monk; Philip Stanier; Caroline A Sewry; Gudrun E Moore; Francesco Muntoni
Journal:  Am J Hum Genet       Date:  2006-09-21       Impact factor: 11.025

Review 4.  Molecular genetics of schizophrenia: past, present and future.

Authors:  Suman Prasad; Prachi Semwal; Smita Deshpande; Triptish Bhatia; V L Nimgaonkar; B K Thelma
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

Review 5.  Methylation matters.

Authors:  J F Costello; C Plass
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

6.  Investigation of the G protein subunit Galphaolf gene (GNAL) in attention deficit/hyperactivity disorder.

Authors:  Nancy Laurin; Abel Ickowicz; Tejaswee Pathare; Molly Malone; Rosemary Tannock; Russell Schachar; James L Kennedy; Cathy L Barr
Journal:  J Psychiatr Res       Date:  2006-12-12       Impact factor: 4.791

7.  Schizophrenia and birthplace of paternal and maternal grandfather in the Jerusalem perinatal cohort prospective study.

Authors:  S Harlap; M C Perrin; L Deutsch; K Kleinhaus; S Fennig; D Nahon; A Teitelbaum; Y Friedlander; D Malaspina
Journal:  Schizophr Res       Date:  2009-04-09       Impact factor: 4.939

Review 8.  Epigenetic mechanisms in schizophrenia.

Authors:  Tania L Roth; Farah D Lubin; Monsheel Sodhi; Joel E Kleinman
Journal:  Biochim Biophys Acta       Date:  2009-06-25

9.  Bulk segregant RNA-seq reveals expression and positional candidate genes and allele-specific expression for disease resistance against enteric septicemia of catfish.

Authors:  Ruijia Wang; Luyang Sun; Lisui Bao; Jiaren Zhang; Yanliang Jiang; Jun Yao; Lin Song; Jianbin Feng; Shikai Liu; Zhanjiang Liu
Journal:  BMC Genomics       Date:  2013-12-30       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.